How AbraSilver Resource Corp. is using Condoryacu to widen the strategic upside at Diablillos before feasibility results (TSX: ABRA)
What this small Australia acquisition reveals about Arthur J. Gallagher & Co.’s bigger strategy (NYSE: AJG)
What the Blacklane acquisition means for Uber Technologies, Inc.’s luxury and corporate travel ambitions (NYSE: UBER)
Why Flex Ltd.’s $1.1bn EP2 acquisition signals rising confidence in U.S. grid modernization spending (NASDAQ: FLEX)
Read More Pharma Industry News Rani Therapeutics seals $1.085bn Chugai deal and $60m oversubscribed financing to fuel oral biologics push Rani Therapeutics secured a $1.085 B Chugai collaboration and an oversubscribed $60.3 M raise. Find out how this dual deal could redefine its biotech trajectory. bySoujanya RaviOctober 17, 2025